Followers | 228 |
Posts | 14879 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Thursday, July 31, 2014 9:43:17 PM
I’m with you on being long NWBO. I trade in and out of all my other stocks - but have not with NWBO since 11/20 when I traded out the first and only time. Pertaining to your questions, here’s my take:
66th, 88th and 110th event:
According to Sid (Akasidney) on his modeling of the trial - based on Pyrr’s figures - which I have reasons to believe are probably very accurate:
The 88th event would occur between July and August.
The 110th event would occur in December.
I'm not sure if Sid is still comfortable with this modeling proposal. Sid, if you’re out there, let us know if you still feel pretty good about it (and if I got anything wrong).
http://www.investorvillage.com/smbd.asp?mb=6543&mn=1457&pt=msg&mid=13923251
Pending vs. Outstanding:
On March 7, 2014, NWBO released their PR indicating that they’d received a “continue” on the Phase III L trial based on safety from the DMC (or the Data Safety Monitoring Board - DSMB). The PR also stated that the efficacy data was “pending”.
http://finance.yahoo.com/news/nw-bio-receives-recommendation-continue-130000641.html
Then on March 13, 2014 - their 8-K for that same PR came out for both that PR and the German HE press release. In the description of what the above PR contained, that section described the “efficacy data is still outstanding” - and the word used was no longer “pending”. I’m not sure but I think I may have noticed that first as I mentioned on Yahoo MB right away as I immediately noticed the double entendre. I just joked about it. But I think since then that we’ve all come to think (hope) it may have had more meaning than that. I’m sure those blinded at NWBO are only guessing, as are we. But as many more qualified than I have indicated, by going through all the data, etc., and the fact that we haven’t heard about the 88th event, it may, in fact be outstanding. (I’m going through all this for our latest prolific board member, Xena, too).
Recruiting Patients:
http://clinicaltrials.gov/ct2/show/study/NCT00045968?term=dcvax+l&rank=3&show_locs=Y#locn
According to the clinical trials site, they are still recruiting patients. One assumes they are still recruiting as they’ve opened the trials in Germany and the UK for that purpose. So I guess that answers that.
Why Would They Still Have to Recruit if the Results were so Good?
As others have indicated, to qualify, there is a long list of inclusion criteria. From what I’ve read on cancer compass, so many people that are diagnosed with GBM are rather at the “mercy” of the physician in charge of their care. If the surgeon does not reference the “L” trial, and the patient has a surgical removal of the tumor - and it’s not saved - well that’s that. They can’t enter the L trial because there is no tumor to make the vaccine. (Xena - L requires a tumor sample - Direct’s vaccine is taken directly from the blood).
It may also have to do with the locations too. Perhaps each location is alloted a certain number of patients and many have reached their allotment. That would allow some to still come from England and Germany and the more recent centers listed. However, the clinicaltrials list indicates they are ALL recruiting (except Georgetown, which is completed) - which I find interesting. We’ve discussed before why there are so many trial sites - such as the number in my area (Orange, Los Angeles and San Diego Counties) - I think: 6. Some of the OC ones are quite close to one another. Why have so many? Unless you are gearing up for something more than a trial :)
Why no update?
Pyrr goes into this in GREAT detail in his first? article on SA. Xena - Pyrr is Steven. I think Eval summed it up in his answer:
And as Flip, Pyrr, and many others have said, no news on the 88th event is most likely - GOOD.
Could this be a bad sign that we’ve not heard about the 88th event?
Yes - if it’s happened, and they are hiding it from us because it’ll effect the stock price, that would be bad. Linda might go to jail for that though. So methinks she’s too smart to risk that. Otherwise, I can’t think of any other "bad sign". Maybe LTT will come up with something. ;)
Regarding the fact that NWBO isn't responding to your emails:
I’ve never had one email responded to. But I've also had Les answer all my calls. In fact, he answered my call tonight - but he’s at a tennis match and said he’ll call back. He may, or may not, but if not, I’ll just try tomorrow. The links on the website to clinical trials don’t work and that’s an easy fix. I emailed him and the pr people about that and it’s still not fixed. More importantly, the PR person at MD Anderson responded to my email yesterday and indicated he wants to have a “meaningful” conversation with me - if I’ll quit my “mass” emails to the MDA staff (I guess 6 people, including Les, is a mass email). So I spent yesterday composing a very thorough email of what I want answers to. I haven’t heard a “meaningful” response back yet. I’ll wait until tomorrow and if I don't hear back, then I’ll include the other 5 in my “mass” email. I sent an email to them yesterday about the CREW request. But that's another post to be made.
But, I wanted to check with Les to make sure he's okay with me continuing this correspondence with MDA - since there are a “few” here on the board that seem to have concerns about that.
NWBO is never going to respond to your questions about L in an email. First, they’d just be guessing - I’m sure an educated guess at that, but even so - to write something like that to one share holder will never happen. And I’m sure they must get boatloads of similar questions about it. I guess it would be nice if they had a form response so you didn’t feel ignored. But it would probably say something like, “we cannot answer questions about L at this time as it’s a blinded trial.” But please don’t equate them not answering you on these questions as signifying a problem. Try calling Les and asking him why we aren’t hearing about L. Perhaps that would make you feel more comfortable - and I understand that having such a large position in one stock merits feeling comfortable about it.
Talk about eat, drink and sleeping Northwest - wanna know something funny? I think the same day that the first direct results were pr’d, I had a screening procedure and had to be put to sleep like Michael Jackson with propofol. Anyhow, when I woke up, I shouted, “NWBO!” That’s what the anesthesiologist told me later. Then he wanted to know what stock it was. How funny is that?
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM